Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Achieve Life Sciences, Inc. ACHV

Healthcare  —  Biotechnology
7.54 (0.29) (3.70%) as of 25 Sep
Market cap
$814.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Achieve Life Sciences, Inc. (ACHV) Business Profile

Updated before January 2025

Company Overview

Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a clinical-stage pharmaceutical company dedicated to addressing the global smoking and nicotine addiction epidemic. Founded in 1991 and headquartered in Seattle, Washington, the company has a strong focus on developing and commercializing cytisinicline, a plant-based alkaloid with the potential to help individuals quit smoking. Achieve Life Sciences was formed through the merger of OncoGenex Pharmaceuticals and Achieve Life Science in 2017, combining expertise in drug development and addiction treatment. The company is led by an experienced management team, including John Bencich as Chief Executive Officer and Cindy Jacobs, M.D., Ph.D., as President and Chief Medical Officer. Their leadership has been instrumental in advancing the company’s mission to improve global health by reducing smoking-related diseases.

Core Business Segments

Achieve Life Sciences focuses primarily on the development and commercialization of cytisinicline, its flagship product candidate. The company operates within the following core business segments:

Smoking Cessation Therapies

  • Cytisinicline: Cytisinicline is a plant-derived alkaloid that has shown promise as a smoking cessation aid. It works by targeting nicotine receptors in the brain, reducing withdrawal symptoms and the urge to smoke. Cytisinicline has been used in Central and Eastern Europe for decades and is now undergoing clinical trials in the United States and other regions to meet regulatory standards.

Research and Development (R&D)

  • Achieve Life Sciences invests heavily in R&D to expand the potential applications of cytisinicline. The company is exploring its use in addressing other forms of nicotine addiction, such as vaping, and is conducting studies to optimize dosing regimens and delivery methods.

Business Model

Achieve Life Sciences operates as a clinical-stage pharmaceutical company, focusing on the development and eventual commercialization of cytisinicline. The company generates revenue primarily through partnerships, licensing agreements, and potential future sales of its products. Its business model is centered on:

  • Clinical Trials: Achieve conducts rigorous clinical trials to ensure the safety and efficacy of cytisinicline, aiming to secure regulatory approvals in key markets such as the United States and Europe.
  • Partnerships: The company collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its R&D efforts and expand its market reach.
  • Commercialization Strategy: Once approved, Achieve plans to commercialize cytisinicline through direct sales and distribution partnerships, targeting healthcare providers, insurers, and smoking cessation programs.

Strategic Direction

Achieve Life Sciences is committed to addressing the global smoking epidemic and has outlined several strategic priorities:

  • Regulatory Approvals: The company is focused on completing Phase 3 clinical trials for cytisinicline and obtaining regulatory approvals from the U.S. Food and Drug Administration (FDA) and other global regulatory bodies.
  • Market Expansion: Achieve aims to expand its presence in international markets, particularly in regions with high smoking prevalence.
  • Product Diversification: The company is exploring additional applications for cytisinicline, such as treating vaping addiction and other forms of nicotine dependence.
  • Sustainability Goals: Achieve is committed to sustainable practices in its operations and supply chain, ensuring that its products are developed and manufactured responsibly.

Competitive Landscape

Achieve Life Sciences operates in a competitive market, facing competition from both pharmaceutical companies and alternative smoking cessation methods. Key competitors include:

  • Pfizer: Manufacturer of Chantix (varenicline), a prescription medication for smoking cessation.
  • GlaxoSmithKline: Producer of Nicorette gum and patches, widely used over-the-counter nicotine replacement therapies.
  • Johnson & Johnson: Offers smoking cessation products such as Nicoderm CQ patches.
  • Biotech Startups: Emerging companies developing innovative therapies for nicotine addiction.

Achieve differentiates itself through its focus on cytisinicline, which has a unique mechanism of action and a long history of use in Europe.

Risk Factors

Achieve Life Sciences faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for cytisinicline could hinder the company’s commercialization efforts.
  • Market Dependence: The company’s success is heavily reliant on the adoption and sales of cytisinicline, making it vulnerable to market fluctuations and competition.
  • Supply Chain Disruptions: Achieve depends on third-party suppliers for the production of cytisinicline, and any disruptions could affect its ability to meet demand.
  • Financial Risks: As a clinical-stage company, Achieve relies on external funding and may face challenges in securing additional capital.

Recent Developments

Achieve Life Sciences has made significant progress in advancing cytisinicline through clinical trials. Recent developments include:

  • Phase 3 Clinical Trials: The company has initiated Phase 3 trials to evaluate the safety and efficacy of cytisinicline in helping individuals quit smoking.
  • Partnerships: Achieve has entered into collaborations with research institutions to explore new applications for cytisinicline.
  • Regulatory Milestones: The company has engaged with regulatory agencies to streamline the approval process for cytisinicline.
  • Global Developments: The COVID-19 pandemic highlighted the importance of addressing respiratory health, increasing awareness of smoking cessation efforts.

Investment Considerations

Investors considering Achieve Life Sciences should weigh the following factors:

Strengths

  • Innovative Product: Cytisinicline offers a unique approach to smoking cessation, with potential advantages over existing therapies.
  • Experienced Leadership: The company’s management team has a proven track record in pharmaceutical development.
  • Growing Market: The global smoking cessation market is expanding, driven by increasing awareness of the health risks associated with smoking.

Risks

  • Regulatory Uncertainty: The approval process for cytisinicline is complex and time-consuming.
  • Financial Dependence: Achieve relies on external funding and may face challenges in raising additional capital.
  • Market Competition: The company competes with established players and alternative therapies in the smoking cessation market.

Conclusion

Achieve Life Sciences, Inc. is well-positioned to address the global smoking epidemic through its innovative product, cytisinicline. With a strong focus on R&D, strategic partnerships, and market expansion, the company has the potential to make a significant impact on public health. However, investors should carefully consider the risks associated with regulatory approvals, market competition, and financial sustainability. As Achieve progresses toward commercialization, it remains a promising player in the smoking cessation market with a focus on long-term growth and innovation.